# Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT00481078** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 94 (actual)

## Conditions studied

- Recurrent Non-small Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** paclitaxel
- **DRUG:** carboplatin
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00481078
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2014-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481078, "Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00481078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*